5 Oversold Growth Stocks to Invest In Now

4. Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Number of Hedge Fund Holders: 18

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) is one of the best oversold growth stocks to invest in now. H.C. Wainwright lifted the price target on Eton Pharmaceuticals, Inc. (NASDAQ:ETON) to $57 from $52 on May 15, reaffirming a Buy rating on the shares and citing the company’s elevated fiscal 2026 revenue guidance and confidence in its growth strategy for the target bump. The firm further told investors in a research note that the company’s stated long-term goals could be achievable, given its execution to date.

The rating update came after Eton Pharmaceuticals, Inc. (NASDAQ:ETON) reported its fiscal Q1 2026 results on May 14, reporting product sales of $24.3 million for the quarter, reflecting a 73% growth over Q1 2025. It also raised its full-year revenue guidance, and now anticipates 2026 revenue to surpass $120 million, up from previous guidance of $110 million. The company further reported that fiscal Q1 2026 fully diluted GAAP EPS was $0.05, non-GAAP fully diluted EPS was $0.14, and adjusted EBITDA reached $5.7 million. Eton Pharmaceuticals, Inc. (NASDAQ:ETON) also received FDA approval for and launched DESMODA™, while also acquiring and relaunching HEMANGEOL®.

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) is a pharmaceutical company that develops and sells treatments for rare diseases. The company focuses on bringing therapies to patients with limited treatment options.

1281292 - 11759070 - 1